| Reference |
|---|
Carre xf1 o J, Lerman B, Singh G, Abbad A, Yellin T, Ehrenhaus J, et al. XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies. MBio. 2025;16:e0360724 pubmed publisher |
Dolange V, Slamanig S, Abdeljawad A, Lai T, Lemus N, Singh G, et al. A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern. J Infect Dis. 2025;231:e723-e733 pubmed publisher |
Tong X, Wang Q, Jung W, Chicz T, Blanc R, Parker L, et al. Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques. iScience. 2024;27:110174 pubmed publisher |
Jung W, Abdelnour A, Kaplonek P, Herrero R, Shih Lu Lee J, Barbati D, et al. SARS-CoV-2 infection prior to vaccination amplifies Fc-mediated humoral profiles in an age-dependent manner. Cell Rep. 2024;43:114684 pubmed publisher |
Barnett C, Krolikowski K, Postelnicu R, Mukherjee V, Sulaiman I, Chung M, et al. Impaired immune responses in the airways are associated with poor outcome in critically ill COVID-19 patients. ERJ Open Res. 2024;10: pubmed publisher |
Zhou F, Vahokoski J, Langeland N, Cox R. Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. NPJ Vaccines. 2024;9:37 pubmed publisher |
Heo C, Lim W, Yang J, Son S, Kim S, Kim D, et al. Novel S2 subunit-specific antibody with broad neutralizing activity against SARS-CoV-2 variants of concern. Front Immunol. 2023;14:1307693 pubmed publisher |
Buffington J, Duan Z, Kwon H, Hong J, Li D, Feng M, et al. Identification of nurse shark VNAR single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2. FASEB J. 2023;37:e22973 pubmed publisher |
Jia T, Wu Y, Liao G, Lei Y, Wu Z, Yang F, et al. Stable and durable antibody responses in SARS-recovered donors vaccinated with inactivated SARS-CoV-2 vaccine. J Med Virol. 2023;95:e28662 pubmed publisher |
Carre xf1 o J, Raskin A, Singh G, Tcheou J, Kawabata H, Gleason C, et al. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Sci Transl Med. 2023;15:eabo2847 pubmed publisher |
Langel S, Garrido C, Phan C, Travieso T, Kirshner H, DeMarco T, et al. Dam-Infant Rhesus Macaque Pairs to Dissect Age-Dependent Responses to SARS-CoV-2 Infection. Immunohorizons. 2022;6:851-863 pubmed publisher |
LaSalle T, Gonye A, Freeman S, Kaplonek P, Gushterova I, Kays K, et al. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients. Cell Rep Med. 2022;3:100779 pubmed publisher |
Jia L, Weng S, Wu J, Tian X, Zhang Y, Wang X, et al. Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. Gut Microbes. 2022;14:2117503 pubmed publisher |
Sano K, Bhavsar D, Singh G, Floda D, Srivastava K, Gleason C, et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nat Commun. 2022;13:5135 pubmed publisher |
Wang C, Li Y, Kaplonek P, Gentili M, Fischinger S, Bowman K, et al. The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia. MBio. 2022;:e0157722 pubmed publisher |
Junker D, Becker M, Wagner T, Kaiser P, Maier S, Grimm T, et al. Antibody binding and ACE2 binding inhibition is significantly reduced for both the BA1 and BA2 omicron variants. Clin Infect Dis. 2022;: pubmed publisher |
Zimmerman O, Altman Doss A, Kaplonek P, Liang C, Vanblargan L, Chen R, et al. mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes. Cell Rep Med. 2022;3:100653 pubmed publisher |
Tzeng T, Chai K, Shen K, Yu C, Yang S, Huang W, et al. A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection. NPJ Vaccines. 2022;7:60 pubmed publisher |
Ma Y, Wang Y, Dong C, Gonzalez G, Zhu W, Kim J, et al. SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. Small. 2022;18:e2200836 pubmed publisher |
Chen Y, Tong P, WHITEMAN N, Moghaddam A, Zarghami M, Zuiani A, et al. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Sci Immunol. 2022;:eabp8328 pubmed publisher |
Walters J, Schouest B, Patel A, Reuschel E, Schultheis K, Parzych E, et al. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. Vaccine. 2022;40:2960-2969 pubmed publisher |
Wang X, Sanborn M, Dai Y, Rehman J. Temporal transcriptomic analysis using TrendCatcher identifies early and persistent neutrophil activation in severe COVID-19. JCI Insight. 2022;7: pubmed publisher |
Mast F, Fridy P, Ketaren N, Wang J, Jacobs E, Olivier J, et al. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. elife. 2021;10: pubmed publisher |
Chang X, Zeltins A, Mohsen M, Gharailoo Z, Zha L, Liu X, et al. A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. Vaccines (Basel). 2021;9: pubmed publisher |
Verma A, Hawes C, Lakshmanappa Y, Roh J, Schmidt B, Dutra J, et al. Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. Cell Rep. 2021;37:109942 pubmed publisher |
Langellotto F, Dellacherie M, Yeager C, Ijaz H, Yu J, Cheng C, et al. A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens. Adv Healthc Mater. 2021;10:e2101370 pubmed publisher |
Shroff R, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle M, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27:2002-2011 pubmed publisher |
Kramer K, Johnson N, Shiakolas A, Suryadevara N, Periasamy S, Raju N, et al. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Rep. 2021;37:109784 pubmed publisher |
Nassir N, Tambi R, Bankapur A, Al Heialy S, Karuvantevida N, Khansaheb H, et al. Single-cell transcriptome identifies FCGR3B upregulated subtype of alveolar macrophages in patients with critical COVID-19. iScience. 2021;24:103030 pubmed publisher |
Tong P, Gautam A, Windsor I, Travers M, Chen Y, Garcia N, et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell. 2021;184:4969-4980.e15 pubmed publisher |
Super M, Doherty E, Cartwright M, Seiler B, Langellotto F, Dimitrakakis N, et al. Biomaterial vaccines capturing pathogen-associated molecular patterns protect against bacterial infections and septic shock. Nat Biomed Eng. 2021;: pubmed publisher |
Jennewein M, MacCamy A, Akins N, Feng J, Homad L, Hurlburt N, et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. 2021;36:109353 pubmed publisher |
Garrido C, Hurst J, Lorang C, Aquino J, Rodriguez J, Pfeiffer T, et al. Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. JCI Insight. 2021;6: pubmed publisher |
Garrido C, Curtis A, Dennis M, Pathak S, Gao H, Montefiori D, et al. SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Sci Immunol. 2021;6: pubmed publisher |
Williams W, Meyerhoff R, Edwards R, Li H, Manne K, Nicely N, et al. Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell. 2021;184:2955-2972.e25 pubmed publisher |
Youn Y, Lee Y, Kim S, Jin H, Bae J, Hong C. Nucleocapsid and Spike Proteins of SARS-CoV-2 Drive Neutrophil Extracellular Trap Formation. Immune Netw. 2021;21:e16 pubmed publisher |
Mast F, Fridy P, Ketaren N, Wang J, Jacobs E, Olivier J, et al. Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2. bioRxiv. 2021;: pubmed publisher |
Dejnirattisai W, Zhou D, Ginn H, Duyvesteyn H, Supasa P, Case J, et al. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021;184:2183-2200.e22 pubmed publisher |
Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12:1577 pubmed publisher |
Gao L, Zhou J, Yang S, Wang L, Chen X, Yang Y, et al. The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity. Signal Transduct Target Ther. 2021;6:113 pubmed publisher |
Pradenas E, Trinit xe9 B, Urrea V, Marfil S, xc1 vila Nieto C, Rodr xed guez de la Concepci xf3 n M, et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med (N Y). 2021;2:313-320.e4 pubmed publisher |
Shaan Lakshmanappa Y, Elizaldi S, Roh J, Schmidt B, Carroll T, Weaver K, et al. SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nat Commun. 2021;12:541 pubmed publisher |
Zohar T, Loos C, Fischinger S, Atyeo C, Wang C, Slein M, et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell. 2020;183:1508-1519.e12 pubmed publisher |
Chen Y, Zuiani A, Fischinger S, Mullur J, Atyeo C, Travers M, et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell. 2020;183:1496-1507.e16 pubmed publisher |
Ripperger T, Uhrlaub J, Watanabe M, Wong R, Castaneda Y, Pizzato H, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity. 2020;53:925-933.e4 pubmed publisher |
Sohn K, Lee S, Kim H, Cheon S, Jeong H, Lee J, et al. COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis. J Korean Med Sci. 2020;35:e343 pubmed publisher |
Elizaldi S, Lakshmanappa Y, Roh J, Schmidt B, Carroll T, Weaver K, et al. SARS-CoV-2 infection induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Res Sq. 2020;: pubmed publisher |
Elizaldi S, Lakshmanappa Y, Roh J, Schmidt B, Carroll T, Weaver K, et al. SARS-CoV-2 infection induces germinal center responses with robust stimulation of CD4 T follicular helper cells in rhesus macaques. bioRxiv. 2020;: pubmed publisher |
Acharya P, Williams W, Henderson R, Janowska K, Manne K, Parks R, et al. A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies. bioRxiv. 2020;: pubmed publisher |
Feng S, Luan X, Wang Y, Wang H, Zhang Z, Wang Y, et al. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein. Infect Genet Evol. 2020;85:104419 pubmed publisher |
Ravichandran S, Coyle E, Klenow L, Tang J, Grubbs G, Liu S, et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci Transl Med. 2020;12: pubmed publisher |
